{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:29:25Z","timestamp":1780086565759,"version":"3.54.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ejca.2010.08.013","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T10:31:48Z","timestamp":1284719508000},"page":"65-73","source":"Crossref","is-referenced-by-count":39,"title":["The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: A single-institution study"],"prefix":"10.1016","volume":"47","clinical-trial-number":[{"clinical-trial-number":"2006-000070-67","registry":"10.18810\/euctr"},{"clinical-trial-number":"nct00381901","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lucas","family":"Caussa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlia M.","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Gault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Savignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Dendale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Fourquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Bollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4785","key":"10.1016\/j.ejca.2010.08.013_b0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"4905","key":"10.1016\/j.ejca.2010.08.013_b0010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ejca.2010.08.013_b0015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ejca.2010.08.013_b0200","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"9555","key":"10.1016\/j.ejca.2010.08.013_b0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejca.2010.08.013_b0020","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2010.08.013_b0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.2003.04.171","article-title":"Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review","volume":"21","author":"Huang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2010.08.013_b0030","first-page":"1113","article-title":"Sensitization of breast cancer cells to radiation by trastuzumab","volume":"2","author":"Liang","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"10.1016\/j.ejca.2010.08.013_b0035","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"9503","key":"10.1016\/j.ejca.2010.08.013_b0045","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","article-title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials","volume":"366","author":"Clarke","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejca.2010.08.013_b0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.ejca.2010.08.013_b0055","first-page":"144","volume":"16","author":"Balaton","year":"1996","journal-title":"Ann Pathol"},{"issue":"2","key":"10.1016\/j.ejca.2010.08.013_b0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0360-3016(79)90729-6","article-title":"Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast","volume":"5","author":"Harris","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ejca.2010.08.013_b0065","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2010.08.013_b0070","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1158\/1078-0432.CCR-08-0030","article-title":"Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial","volume":"14","author":"Pierga","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.08.013_b0210","doi-asserted-by":"crossref","unstructured":"Roche H, Fumoleau P, Spielmann M, et al. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 trial. J Clin Oncol 2006.","DOI":"10.1200\/JCO.2006.07.3916"},{"issue":"14","key":"10.1016\/j.ejca.2010.08.013_b0075","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.ejca.2006.03.026","article-title":"Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study","volume":"42","author":"Bollet","year":"2006","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2010.08.013_b0080","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijrobp.2007.12.059","article-title":"How to boost the breast tumor bed? A multidisciplinary approach in eight steps","volume":"72","author":"Kirova","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.ejca.2010.08.013_b0085","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1245\/s10434-006-9331-2","article-title":"Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy","volume":"14","author":"Alran","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2010.08.013_b0090","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.ijrobp.2004.08.051","article-title":"Breast radiotherapy in the lateral decubitus position: a technique to prevent lung and heart irradiation","volume":"61","author":"Campana","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"946","key":"10.1016\/j.ejca.2010.08.013_b0095","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1259\/bjr\/23839243","article-title":"Breast radiotherapy in women with pectus excavatum (funnel chest): is the lateral decubitus technique an answer? A dosimetric study","volume":"79","author":"Bollet","year":"2006","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ejca.2010.08.013_b0100","unstructured":"ICRU. Report 50: Prescribing, recording, and reporting photon beam therapy. Washington (DC): International Commission on Radiation Units and Measurements; 1993."},{"issue":"2","key":"10.1016\/j.ejca.2010.08.013_b0215","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0167-8140(00)00152-3","article-title":"Cardiac and lung complication probabilities after breast cancer irradiation","volume":"55","author":"Hurkmans","year":"2000","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2010.08.013_b0220","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0360-3016(02)03741-0","article-title":"The impact of central lung distance, maximal heart distance, and radiation technique on the volumetric dose of the lung and heart for intact breast radiation","volume":"54","author":"Kong","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ejca.2010.08.013_b0105","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ijrobp.2007.05.007","article-title":"Postmastectomy electron beam chest wall irradiation in women with breast cancer: a clinical step toward conformal electron therapy","volume":"69","author":"Kirova","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ejca.2010.08.013_b0110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.radonc.2006.05.014","article-title":"CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning","volume":"79","author":"Kirova","year":"2006","journal-title":"Radiother Oncol"},{"issue":"992","key":"10.1016\/j.ejca.2010.08.013_b0115","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1259\/bjr\/28834220","article-title":"Simplified rules for everyday delineation of lymph node areas for breast cancer radiotherapy","volume":"83","author":"Kirova","year":"2010","journal-title":"Br J Radiol"},{"issue":"979","key":"10.1016\/j.ejca.2010.08.013_b0120","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1259\/bjr\/96865511","article-title":"Anatomical, clinical and radiological delineation of target volumes in breast cancer radiotherapy planning: individual variability, questions and answers","volume":"82","author":"Castro Pena","year":"2009","journal-title":"Br J Radiol"},{"issue":"992","key":"10.1016\/j.ejca.2010.08.013_b0195","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1259\/bjr\/28834220","article-title":"Simplified rules for everyday delineation of lymph node areas for breast cancer radiotherapy","volume":"83","author":"Kirova","year":"2010","journal-title":"Br J Radiol"},{"issue":"34","key":"10.1016\/j.ejca.2010.08.013_b0130","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1200\/JCO.2007.14.0657","article-title":"Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?","volume":"25","author":"Ewer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2010.08.013_b0135","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/annonc\/mdn029","article-title":"Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study","volume":"19","author":"Belkacemi","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.08.013_b0140","doi-asserted-by":"crossref","unstructured":"Romestaing P, Hennequin C, Bosset JF, et al. Elective irradiation of Internal Mammary Chain (IMC) after mastectomy has no impact on 10y overall survival in breast cancer \u2013 results of a randomized phase III study in France. In: EBCC7; 2010; Barcelona, Spain: Eur J Cancer; 2010. p. 54.","DOI":"10.1016\/S1359-6349(10)70032-X"},{"issue":"1","key":"10.1016\/j.ejca.2010.08.013_b0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/02841860903352959","article-title":"Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922\/10925)","volume":"49","author":"Matzinger","year":"2010","journal-title":"Acta Oncol"},{"issue":"9188","key":"10.1016\/j.ejca.2010.08.013_b0150","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(99)02245-X","volume":"354","author":"Hojris","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2010.08.013_b0155","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.radonc.2008.09.003","article-title":"Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study","volume":"90","author":"Shaffer","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2010.08.013_b0160","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.ijrobp.2008.06.970","article-title":"Radiation treatments may contribute to the development of cardiac dysfunction in breast cancer patients treated with chemotherapy and trastuzumab","volume":"72","author":"Alm En-Din","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2010.08.013_b0165","unstructured":"Magne N, Chargari C, Macdermed D, et al. Tomorrow\u2019s targeted therapies in breast cancer patients: What is the risk for increased radiation-induced cardiac toxicity? Crit Rev Oncol Hematol, in press."},{"issue":"20","key":"10.1016\/j.ejca.2010.08.013_b0170","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa0707064","article-title":"Use of multiple biomarkers to improve the prediction of death from cardiovascular causes","volume":"358","author":"Zethelius","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2010.08.013_b0175","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(05)70251-5","article-title":"Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300, 000 women in US SEER cancer registries","volume":"6","author":"Darby","year":"2005","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2010.08.013_b0180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0971-6203.54849","article-title":"Technique alternatives for breast radiation oncology: conventional radiation therapy to tomotherapy","volume":"34","author":"Fournier-Bidoz","year":"2009","journal-title":"J Med Phys"},{"key":"10.1016\/j.ejca.2010.08.013_b0185","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.ijrobp.2005.07.097","article-title":"Concurrent trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer","volume":"63","author":"Bellon","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.ejca.2010.08.013_b0190","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","article-title":"Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831","volume":"27","author":"Halyard","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910008361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910008361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T21:29:51Z","timestamp":1559683791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910008361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0959804910008361"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.08.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}